IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?

Lamartina Livia, Montesano Teresa, Falcone Rosa, Biffoni Marco, Grani Giorgio, Maranghi Marianna, Ciotti Laura, Giacomelli Laura, Ramundo Valeria, Lo Monaco Cristiano, Di Gioia Cira Rosaria, Lucia Peirnatale, Ronga Giuseppe, Durante Cosimo
  • Endocrine Practice, November 2018, AACE Corp (American Association of Clinical Endocrinologists)
  • DOI: 10.4158/ep-2018-0393

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.4158/ep-2018-0393

The following have contributed to this page: Dr. Giorgio Grani